Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 8(1): 10702, 2018 Jul 16.
Article in English | MEDLINE | ID: mdl-30013226

ABSTRACT

Electronic cigarette has the potential to serve as a tobacco cessation aid if the prerequisites which are safety and efficacy in term of nicotine delivery are achieved. The nicotine-based liquids are mainly composed by propylene glycol and glycerol playing the important role of airborne carriers. 1,3 propanediol is proposed as a propylene glycol substitute to potentially improve the thermal stability, nicotine delivery and to decrease inhaled flavors concentrations. We have implemented various thermal, physicochemical and computational methods to evaluate the use of 1,3 propanediol as a substitute (or additional ingredient) to propylene glycol in e-liquids compositions. Our results indicate that 1,3 propanediol is stable upon heating when electronic cigarette are used in recommended conditions. We demonstrate that 1,3 propanediol gave better thermic profile compared to propylene glycol and glycerol, showing less thermal decomposition by-products. In addition, 1,3 propanediol gives to nicotine a more basic environment ensuring a high level of free base nicotine form. We have also established a quantum mechanical based computational method to validate e-liquids as flavor enhancer. Our findings showed that globally 1,3 propanediol seems to have better flavoring properties than glycerol and propylene glycol. Finally, 1,3 propanediol seems to induce quite similar aerodynamic properties compared to propylene glycol and glycerol.


Subject(s)
Electronic Nicotine Delivery Systems/methods , Flavoring Agents/chemistry , Nicotine/administration & dosage , Propylene Glycol/chemistry , Propylene Glycols/chemistry , Computer Simulation , Flavoring Agents/adverse effects , Glycerol/chemistry , Hot Temperature , Models, Chemical , Propylene Glycol/adverse effects , Propylene Glycols/adverse effects , Proton Magnetic Resonance Spectroscopy , Tobacco Use Cessation Devices
2.
J Periodontol ; 76(8): 1329-38, 2005 Aug.
Article in English | MEDLINE | ID: mdl-16101366

ABSTRACT

BACKGROUND: In this study we examine the properties of a vegetable extract from seeds of Lupinus albus (LU 105). In previous works we demonstrated that LU 105 reduced the expression, by gingival fibroblasts, of both matrix metalloproteinase (MMP)-2 and MMP-9. We decided to study the impact of LU 105 on cell proliferation and morphology. Using organ culture media we also studied the MMP and tissue inhibitors of metalloproteinases (timp) expression AND THE cytokines secretion. METHODS: Healthy and inflamed gingival biopsies were placed in appendage culture with or without LU 105. The organ culture media were analyzed using Western blottings (MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13, TIMP-1, and TIMP-2) and gelatine zymography. A reverse transcription polymerase chain reaction (RT-PCR) was also performed on healthy and inflamed gingival biopsies, which were maintained in culture with or without LU 105 0.1%. Then, we decided to determine the amount of cytokines present in the organ culture media such as interleukin (IL)-1 beta, IL-4, IL-6, transforming growth factor (TGF)-beta, and tumor necrosis factor (TNF)-alpha. RESULTS: When gingival biopsies derived from inflamed tissues were cultured with LU 105 0.1% in the culture media, the MMP and TIMP expression and activity decreased significantly when compared to cultures without LU 105. Moreover, we did not note any statistical difference in the cell proliferation compared with human gingival fibroblast cultures without LU 105. Furthermore, IL-1 beta, IL-6, TGF-beta, and TNF-alpha amounts in the culture media decreased significantly, whereas IL-4 increased significantly when LU 105 0.1% was added to the culture media. CONCLUSION: LU 105, a novel metalloproteinase inhibitor with few consequences on cell proliferation and morphology, is a vegetable extract with potential clinical capacity.


Subject(s)
Gingiva/drug effects , Gingivitis/enzymology , Lupinus , Metalloproteases/antagonists & inhibitors , Oligopeptides/pharmacology , Plant Extracts/pharmacology , Protease Inhibitors/pharmacology , Analysis of Variance , Cell Proliferation/drug effects , Cell Shape/drug effects , Cells, Cultured , Cytoskeleton/drug effects , Enzyme-Linked Immunosorbent Assay , Fibroblasts/drug effects , Fibroblasts/enzymology , Gingiva/cytology , Gingiva/enzymology , Humans , Interleukins/biosynthesis , Reverse Transcriptase Polymerase Chain Reaction , Seeds , Tissue Inhibitor of Metalloproteinases/antagonists & inhibitors , Transforming Growth Factor beta/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...